HS-20110 / Jiangsu Hansoh Pharma, Roche - LARVOL DELTA

GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer (AACR-NCI-EORTC 2025) - "These preclinical data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."

Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5

Hansoh Pharmaceutical Group has entered into a license agreement with F. Hoffmann-La Roche Ltd, granting Roche an exclusive worldwide license to develop, manufacture, and commercialize Hansoh’s investigational CDH17-targeting antibody-drug conjugate, HS-20110, for colorectal cancer and other solid tumors (TipRanks) - "This agreement, which excludes the Chinese Mainland, Hong Kong, Macau, and Taiwan, involves an upfront payment of $80 million and potential milestone payments up to $1.45 billion, along with tiered royalties on future sales."

Licensing / partnership • Colorectal Cancer

A Study of HS-20110 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=475 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

A Study of HS-20110 in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=475 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P1 trial • Oncology • Solid Tumor

HANSOH PHARMA RECEIVES THE CLINICAL TRIAL APPROVAL FROM NMPA OF ITS HS-20110, A NEW ANTIBODY-DRUG CONJUGATE (ADC) (Hansoh Pharma Press Release) - "Hansoh Pharma...announces that, HS-20110 for injection, which is a new antibody-drug conjugate (ADC) independently developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China on December 16, 2024, which is intended to be investigated in clinical trials for advanced solid tumors."

New trial • Solid Tumor